Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop